An experimental drug developed by researchers at Michigan Medicine has successfully reversed a severe and often intractable form of fatty liver disease in animal studies. Rather than focusing exclusively on the liver itself, the novel therapy targets an unexpected and critical source of hepatic damage: the gastrointestinal tract.
The compound, designated as DT-109, works by suppressing harmful gut bacteria, fortifying the intestinal lining, and preventing pro-inflammatory substances from migrating into the bloodstream and reaching the liver. According to findings published in The Journal of Clinical Investigation, this gut-centric therapeutic approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, introducing a promising new strategy for managing a condition that has historically challenged medical professionals.
MASH affects approximately 7% of the global population. It represents a severe, progressive manifestation of non-alcoholic fatty liver disease, characterized by the pathological accumulation of excess fat within the liver, which subsequently triggers chronic inflammation and cellular injury. Over extended periods, this unmanaged inflammation can advance to cirrhosis—a condition defined by extensive and irreversible liver scarring—as well as primary liver cancer and terminal liver failure. Although clinical treatment options for liver diseases have seen incremental improvements in recent years, highly effective therapies capable of arresting or reversing the disease process remain severely limited.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Dr. Eugene Chen, senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
How Harmful Gut Bacteria Can Trigger Liver Damage
Dr. Chen’s research team had previously demonstrated that DT-109, a glycine-based tripeptide, could ameliorate MASH symptoms in preliminary animal studies. A tripeptide is a relatively small molecule constructed from three amino acids, which serve as the fundamental building blocks of proteins. However, the precise mechanisms by which the compound produced its protective physiological effects remained unclear.
The latest research provides a comprehensive explanation, illuminating how disruptions in the composition of gut bacteria can initiate a detrimental biochemical chain reaction that ultimately damages the liver, and demonstrating precisely how DT-109 interrupts that pathological cascade.
Prior to evaluating the therapeutic efficacy of the drug, the scientists confirmed a critical contributor to the pathogenesis of MASH: the excessive proliferation of Clostridium perfringens, a bacterium known to generate high levels of ammonia within the intestinal lumen. When intestinal ammonia concentrations rise significantly, they can compromise the structural integrity of the gut’s protective inner lining.
Under normal physiological conditions, this robust intestinal barrier prevents potentially harmful luminal substances, microbial byproducts, and toxins from escaping the digestive tract and entering the systemic circulation. As the barrier weakens and becomes increasingly permeable, however, microbial toxins generated within the gut can freely travel through the bloodstream directly to the liver. Once these toxins accumulate in the hepatic environment, they provoke intense inflammation and trigger localized immune responses that significantly exacerbate liver tissue damage.
One major component of this immune reaction involves the overactivation of CD8+ T cells—specialized immune cells that normally assist the body in identifying and destroying infected or abnormal cells. When these T cells become chronically overactive within the liver, they actively contribute to the destructive inflammatory processes characteristic of MASH. These findings help clarify why a pathology centered within the liver can be profoundly influenced by biological events occurring elsewhere in the digestive system.
Experimental Drug Repairs the Gut and Protects the Liver
Through a rigorous series of controlled experiments, the research team discovered that DT-109 disrupts this destructive physiological cycle by improving the overall intestinal environment and reinforcing the structural integrity of the gut’s protective barrier.
In both murine models and nonhuman primates, administration of the compound successfully reduced populations of Clostridium perfringens and lowered ammonia production within the intestines. These measurable improvements helped fortify the intestinal lining, thereby restricting the translocation of harmful microbial substances into the broader circulatory system and mitigating their capacity to inflict damage upon the liver tissue.
The empirical results were particularly striking in nonhuman primates, whose fundamental liver biology and gut microbial communities bear a much closer resemblance to human physiology than those of standard laboratory mice. In these nonhuman primate models, DT-109 effectively suppressed liver inflammation and diminished the overall histological severity of MASH.
Together, these findings underscore how targeting pathological processes within the gut can yield profound therapeutic benefits within the liver, even though the pharmacological agent acts primarily inside the gastrointestinal tract.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," said Dr. Jifeng Zhang, co-author and research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
The gut-liver axis describes the intricate and bidirectional biological relationship linking the digestive tract and the liver. Because nutrients and substances absorbed from the intestines are transported directly to the liver via the portal venous system, hepatic health is exceptionally sensitive to shifts in gut microbial composition and intestinal barrier permeability. By targeting this intricate physiological connection, DT-109 offers a novel method for addressing the underlying drivers of liver inflammation rather than merely managing the pathological consequences after cellular damage has already occurred.
Potential Benefits Beyond Fatty Liver Disease
Beyond its efficacy in treating fatty liver disease, researchers believe that the compound’s remarkable ability to protect the intestinal barrier could render it useful against a broader spectrum of conditions characterized by chronic inflammation and metabolic dysfunction.
Previous investigations have already demonstrated that DT-109 can reduce the formation of atherosclerotic plaques and inhibit vascular calcification in nonhuman primates. Atherosclerotic plaques consist of lipid deposits and other cellular debris that accumulate progressively within the walls of arteries, potentially restricting vital blood flow and substantially elevating the risk of cardiovascular events. Vascular calcification occurs when calcium deposits harden blood vessel walls, diminishing their natural elasticity and contributing heavily to cardiovascular morbidity.
These expanding observations suggest that DT-109 could eventually find clinical applications in the management of both hepatic and cardiovascular disorders—an important clinical prospect given that metabolic syndromes frequently affect multiple organ systems simultaneously.
Furthermore, the research team is actively exploring whether the compound might provide therapeutic relief for individuals suffering from inflammatory bowel disease (IBD), a classification of chronic gastrointestinal disorders that includes Crohn’s disease and ulcerative colitis. Because defects in intestinal barrier function are strongly implicated in numerous gastrointestinal pathologies, a pharmaceutical intervention designed to reinforce this biological barrier could conceivably offer benefits that extend far beyond liver protection. Nonetheless, rigorous additional investigations will be required to establish whether DT-109 can safely and effectively treat these diverse inflammatory conditions.
A Promising Treatment That Still Needs Human Trials
Despite these highly encouraging preclinical findings, DT-109 remains an experimental pharmaceutical agent. While its capacity to reverse MASH has been robustly documented in advanced animal models, researchers have not yet determined whether the drug can safely and effectively replicate these therapeutic benefits in human patients.
The upcoming phase of research will focus on the continued evaluation of the compound, with the ultimate objective of advancing it toward formal human clinical trials. These forthcoming studies will be indispensable for establishing safety profiles, optimal dosing regimens, and verified clinical efficacy in patient populations.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," said Dr. Elliot Tapper, Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
This discovery reflects a notable paradigm shift in how contemporary scientists conceptualize and approach fatty liver disease. By directly addressing harmful gut bacteria and actively restoring the intestinal barrier, researchers may soon be capable of protecting vital internal organs using therapeutic mechanisms that operate primarily outside the organ itself. If subsequent human trials corroborate the positive outcomes observed in animal models, DT-109 could introduce an entirely new therapeutic paradigm for patients suffering from severe fatty liver disease, while simultaneously addressing overlapping cardiovascular complications.
Funding for the research and related intellectual property disclosures indicate that Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are named as inventors on a patent application concerning tripeptides and the treatment of metabolic, cardiovascular, and inflammatory disorders. Dr. Chen is also listed as an inventor specifically for DT-109. The University of Michigan holds the patent rights for the compound and has licensed it to Diapin Therapeutics, an enterprise in which both Dr. Chen and the university maintain financial ownership interests. Diapin supplied the DT-109 utilized in the study and is actively directing its continued commercial development. All experimental protocols involving human data and nonhuman subjects received formal ethical approval from their respective institutional review boards and animal care committees in accordance with established ethical guidelines and institutional standards.